Omnipod Pod Recall; Afrezza OK’d for Kids 6 and Up; CVS to Cover Zepbound Again

Insulet initiated a voluntary device correction of certain Omnipod pods due to a manufacturing defect that causes insulin to leak rather than being fully delivered into the body, the FDA alerted. This action is separate from the company’s correction issued in March.

The agency also expanded approval of inhaled mealtime insulin (Afrezza) to include children ages 6 years and older with type 1 and type 2 diabetes, said maker MannKind.

From 2007 to 2023, systemic menopausal hormone therapy use among women 40 and older dropped from 4.4% to 1.7%, medical and pharmacy claims data showed. (Mayo Clinic Proceedings)

Genetic testing identified the cause of pancreatic agenesis in 98% of cases, reinforcing the need for early testing to guide treatment, researchers wrote in the Lancet Diabetes & Endocrinology.

Semaglutide (Ozempic, Wegovy) showed mixed results for easing nicotine addiction in a randomized phase II trial. (JAMA Network Open)

CVS Caremark will again cover Eli Lilly’s weight-loss drug tirzepatide (Zepbound) following patient backlash. (NBC News)

Is Eli Lilly’s investigational triple-agonist retatrutide too powerful? (Washington Post)

A review in the Journal of Clinical Endocrinology & Metabolism detailed the potent anti-inflammatory effects of GLP-1 medications, positioning the drugs “as promising candidates for broader therapeutic applications.”

Osteoporosis was tied to a 47% increased risk of mortality among postmenopausal women, national survey data showed. (Menopause)

Participants taking the dual GLP-1/GIP agonist oral ribupatide lost up to 12.1% of their body weight by week 26 with no plateau in a phase II trial, said Kailera Therapeutics. The company also reported an average 16% weight loss by week 12 with its separate triple-agonist in a phase I trial.

Investigational eye drops for diabetic macular edema missed the mark in two phase III trials, said drugmaker Oculis.